Alpha‐Synuclein as a Potential Biomarker for Inclusion Body Myositis in Blood and Muscle
αSN reactivity may serve as an additional immunohistochemical marker for IBM diagnosis. Furthermore, this study indicates that αSN serum concentrations decrease with disease duration and clinical deterioration. Therefore, serum αSN may be provisionally considered a monitoring biomarker in IBM, pending further studies.
Authors
- Kathleen Kleeberg
- Leila Motlagh Scholle (ORCID: https://orcid.org/0000-0003-1363-4726)
- Steffen Naegel (ORCID: https://orcid.org/0000-0003-1727-9362)
- Alexander Mensch (ORCID: https://orcid.org/0000-0003-0089-4473)
- Anne Schänzer (ORCID: https://orcid.org/0000-0002-2014-2028)
- Tobias Mayer (ORCID: https://orcid.org/0000-0002-4935-4710)
- Gisela Stoltenburg‐Didinger (ORCID: https://orcid.org/0000-0002-2534-3064)
- Laurie Foerster
- Lorenzo Barba (ORCID: https://orcid.org/0000-0003-1328-3620)
- Ilka Schneider (ORCID: https://orcid.org/0000-0002-7109-2542)
- Thomas Kendzierski
- Markus Otto (ORCID: https://orcid.org/0000-0003-4273-4267)
- Torsten Kraya (ORCID: https://orcid.org/0000-0002-6060-3810)
- Anna Katharina Koelsch
- K.-S. Delank
Institutions
- Justus-Liebig-Universität Gießen (DE)
- Klinikum St. Georg (DE)
- Alfried Krupp Hospital (DE)
- University Hospital in Halle (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Neuropathology and Applied Neurobiology
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1111/nan.70019
- Citations
- 1
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Baden-Württemberg Stiftung
- Fondation Thierry Latran
- European Commission
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Universität Ulm